Head to Head Analysis: Syros Pharmaceuticals (SYRS) & Vericel Corporation (VCEL)
Syros Pharmaceuticals (NASDAQ: SYRS) and Vericel Corporation (NASDAQ:VCEL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.
Earnings & Valuation
This table compares Syros Pharmaceuticals and Vericel Corporation’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Syros Pharmaceuticals||$1.42 million||412.95||-$48.99 million||($2.13)||-10.48|
|Vericel Corporation||$49.64 million||2.41||-$22.39 million||($1.10)||-3.32|
Vericel Corporation has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Vericel Corporation, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
49.7% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 32.0% of Vericel Corporation shares are held by institutional investors. 3.3% of Vericel Corporation shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares Syros Pharmaceuticals and Vericel Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Syros Pharmaceuticals has a beta of -4.02, indicating that its share price is 502% less volatile than the S&P 500. Comparatively, Vericel Corporation has a beta of 3.1, indicating that its share price is 210% more volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for Syros Pharmaceuticals and Vericel Corporation, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Syros Pharmaceuticals presently has a consensus price target of $21.77, suggesting a potential downside of 2.52%. Vericel Corporation has a consensus price target of $6.33, suggesting a potential upside of 73.52%. Given Vericel Corporation’s stronger consensus rating and higher probable upside, analysts clearly believe Vericel Corporation is more favorable than Syros Pharmaceuticals.
Vericel Corporation beats Syros Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.
About Vericel Corporation
Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.
Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.